Porcine cell and organ transplantation provides promise for maintaining normal physiological conditions in patients with end-stage organ failure. The approach however poses serious risk of transmitting pig pathogens to humans. Among many potential pathogens, porcine endogenous retroviruses (PERV) are of particular concern due to their ubiquitous nature in pigs and capability of infecting human cells. Major antigenic determinants and receptor binding domains on PERV remain unclear until now. Two monoclonal antibodies (mAb), named 8E10 and 7C4 capable of neutralizing PERV infection in HEK293 cells are isolated at an IC 50 of 3.0 and 2.7 μg/ml, respectively, in this work. Epitope location for mAb 8E10 was mapped to amino acids 427-434, residing at the C-terminal region of the gp70 component of type A PERV Env protein. The mAb 8E10 bound directly to the PERV indicating that the epitope is exposed on the virion surface. The mAb 7C4 epitope was assigned to the region comprising amino acids 517-537 on the p15E component of PERV. In contrast to mAb 8E10, the 7C4 mAb bound native PERV inefficiently suggesting that its epitope is accessible only after the virus interacts with its receptor. Finally, both mAbs variable regions were cloned and nucleotide sequence determined. All together, these results reveal that both mAbs 8E10 and 7C4 effectively neutralize PERV infection and may be used as a mean to prevent PERV infection in patients receiving xenotransplantation.
Introduction
Pigs are the most likely donor organ source for various reasons, including organ size, matching physiology, matters of husbandry and ethical objections to using primates, to overcome the severe human organ transplantation shortage. Besides acute rejection, infection associated with pig pathogens is another major concern in using porcine tissues for transplantation. Among many potential pig-associated pathogens, porcine endogenous retroviruses (PERV) attract much attention due to their ubiquitous nature in pigs, and capability in infecting human cells (Le Tissier et al., 1997; Lower et al., 1996) . Approximately 50 copies of PERV integration are reportedly present in the genome of various pig breeds, and at least three subtypes (A, B and C) of PERV are known to exist (Akiyoshi et al., 1998; Patience et al., 2001; Takeuchi et al., 1998) . Several lines of evidence have shown that the risk of pig-to-human PERV transmission in patients treated with pig cells is low (Blusch et al., 2000; Kuddus et al., 2002; Switzer et al., 1999) , although long term PERV infection effects in humans remains to be investigated.
Closely related to PERVs are other mammalian type-C retroviruses such as the gibbon ape leukemia virus, murine leukemia virus (MuLV), feline leukemia virus (FeLV), and baboon endogenous retrovirus (Akiyoshi et al., 1998; Le Tissier et al., 1997) . The PERV genes coding for capsid protein (gag) and reverse transcriptase (pol) show particularly high homology (50-60%) with other C-type retroviruses, whereas the envelope protein (Env) gene is found less conserved among the group. The Env protein is located on the virion surface and is the major retrovirus antigenic determinant (Le Tissier et al., 1997; Takeuchi et al., 1998) . The protein is also responsible for mediating retroviral entry that involves a series of complex events including receptor binding, conformational changes, and membrane fusion between virus and host cells.
Retroviral Env proteins are trimers of heterodimers consisting of one gp70 and one p15E molecule (Kobe et al., 1999) . Both gp70 and p15E derive from intracellular proteolytic processing of the Env precursor protein (Pinter et al., 1997) . The N-terminal domain of gp70 is responsible for binding the virus to cell surface receptor (Akiyoshi et al., 1998; Le Tissier et al., 1997) . The middle protein part is the variable proline-rich region assigned the role of modulating conformation (Lavillette et al., 1998) . The conserved gp70 C-terminal region is also required for viral entry (Gemeniano et al., 2006) and disulfide bonded to p15E, anchored on the viral membrane through several transmembrane domains. Finally, R-peptide, an 18-residue region in the C-terminal cytoplasmic tail of p15E modulates viral particle fusogenicity upon binding to the cell surface receptor (Bobkova et al., 2002; Ragheb and Anderson, 1994; Rein et al., 1994) . The gp70 component undergoes major conformational rearrangements following receptor binding, allowing the p15E protein to become active and trigger viral and cytoplasmic lipid bilayer fusion. The domain organization of PERV Env protein is depicted in Fig. 1 .
Previous PERV research effort has been exerted on studying detection methods, epidemiology, and viral infection outcomes (Clemenceau et al., 1999; Martin et al., 1998) . Few studies concerning antigenic determinants and cell entry mechanism of the virus have been reported (Fiebig et al., 2003; Gemeniano et al., 2006; Langhammer et al., 2005; Watanabe et al., 2005) . This report describes epitope mapping of two neutralizing monoclonal antibodies (mAbs) specific to PERV Env protein. The mAb binding activity to the virions and mAbs variable region sequences are also reported herein. Information availability from this study could facilitate future vaccine and immunosupplement development against PERV infection.
Results

Generation of mAb specific to PERV Env protein and determination of their neutralization activity
A recombinant protein containing the region from amino acid positions 332 to 615 ) of the Env protein of type A PERV (GenBank accession number AF296168), derived originally from the ST-IOWA pig strain, was used as the mice immunization antigen. Several reasons explain using the Cterminal half of PERV Env protein as the antigen. First, this region is more evolutionally conserved than the N-terminal half and hence has a higher chance to obtain mAbs that could recognize different PERV serotypes. Second, the C-terminal region is demonstrably essential for PERV binding to the receptor (Watanabe et al., 2005) . Third, neutralizing antibodies have been successfully generated in a related FeLV using Env protein C-terminal region as the antigen (Langhammer et al., 2005) . Approximately 30 mAbs reacting positively with Env 332-615 were obtained using standard hybridoma techniques. These mAbs were further tested for their neutralization activity on PERV infection. Two mAbs, designated 8E10 and 7C4, displayed a dose-dependent inhibition curve of PERV infection in HEK293 cells as demonstrated in Fig. 2 . In contrast, mAb CT3.3, specific to the Epstein-Barr virus latent membrane protein 1 (LMP1) (Fang et al., 2004) , did not show any neutralizing activity against PERV infection. The concentration of 8E10 and 7C4 mAb required to achieve 50% inhibition (IC 50 ) of PERV infection was 3 and 2.7 μg/ml, respectively. As mAb neutralization activities were considered relatively weak, this work further examined whether 7C4 and 8E10 mAb activity is specific to PERV by investigating mAb effect on infectivity of a recombinant MuLV harboring the gfp reporter gene. Results indicated that neither mAb exhibited significant neutralization on the recombinant MuLV as determined by the flow cytometer assay, reflecting 7C4 and 8E10 mAb high specificity to PERV (Fig. 2) .
Epitope mapping of the anti-Env mAb 8E10 and 7C4
The epitope recognized by 8E10 mAb was mapped using a series of thioredoxin-fused Env protein fragments in either immunoblotting assays or ELISA (Fig. 3) . Besides that of the ST- IOWA type A PERV, several other PERV type Env proteins were also utilized to determine mAb specificity. The origin of these Env proteins include: PK-A, derived from a type A PERV of PK15 (GenBank accession number AJ293656); PK-B, derived from a type B PERVof PK15 (AJ293657); PBMC-C, from a type-C PERV of pig peripheral blood mononuclear cells (AF038600). The relative position of these fragments on the Env protein are shown in Fig. 3A , and their electrophoretic profile and Western blotting analysis results as detected using mAb 8E10 and 7C4 are shown in Fig. 3B . A similar study using the same set of recombinant proteins in an ELISA was also performed and the result is shown in Fig. 3C . Our results indicated that the mAb 8E10 could recognize the PERV Env 332-615 protein and its two truncated derivatives comprising the region from amino acid 382 to 434 (Fig. 3B ). On the other hand, the mAb was unable to detect any recombinant Env protein extending from amino acid 417 to the C-terminus. By combining these data, the epitope site recognized by 8E10 mAb could be mapped to amino acid positions 417-434 of the PERV Env protein. Besides the Env proteins of PERV type A strains, 8E10 mAb could detect the recombinant PK-B Env fragment corresponding to the region from amino acid 363 to 434 in PK-A Env, whereas the mAb failed to recognize a PK-B Env fragment comprising amino acids 363 to 426 (Figs. 3C and D). Multiple sequence alignment of the region of amino acid 417-434 of PERV-A Env with that of PK-B revealed three mismatches clustered at positions 417, 420, and 421 (Fig. 4) . This finding further located the most likely epitope position for this mAb to the region of amino acids 422 to 434 in PERV-A Env. A similar approach found that mAb 7C4 could detect all recombinant type A Env proteins containing the region from amino acid 517 to 539 on the p15E molecule. The mAb did not react with the PK-B Env protein fragment corresponding to the region from amino acid 513 to 557 of type A PERV Env protein (Fig. 4) . The result strongly suggested that 7C4 mAb is specific to PERV-A.
Verification of the mAb binding sites by competition ELISA
A competition ELISA using Env 332-615 as the immobilized antigen was performed to further verify epitopes mapped by Western blotting and ELISA. All recombinant proteins containing the region 417-434, including Env332-615, Env 397-481 , and PK-B Env 363-434 could effectively block 8E10 mAb binding to the antigen coated on plates (Fig. 5A) . The IC 50 of these proteins in the ELISA was approximately 1 μg/ml. A synthetic peptide, consisting of sequence YPEKAVLDEYDYRYNRPK, corresponding to the region 417-434 of PERV-A Env (Fig. 4) , could also block interaction between 8E10 mAb and Env 332-615 with an IC50 at approximately 4.5 μg/ml. None of BSA, Env 1-331 , nor PK-B Env 363-434 exhibited any assay competition effect (Fig.  5A) . Together, the results indicated that the amino acid sequence of Env 427-434 could be recognized specifically by 8E10 mAb.
A similar experiment was performed to verify the 7C4 mAb binding site. Both Env 332-615 and Env 460-539 recombinant proteins exhibited strong inhibition activity for 7C4 mAb binding to the immobilized antigen Env (Fig. 5B) . On the other hand, PK-B Env 540-584 did not show any inhibition as also found when BSA was used as a competitor. Concentration of these proteins required to achieve 50% reaction inhibition was approximately 2 μg/ml.
Binding of the mAbs to PERV
A virus capture assay was performed to determine whether these mAbs neutralized PERV infection through direct binding to the virions. The assay is based on detecting viral genomic RNA presence by RT-PCR amplification of the region from nucleotide 886 to 1007 of the viral gag gene (GenBank Fig. 4 . Comparison of the sequences around the epitopic sites of the two mAb among different PERV Env proteins. The underlined sequences are the epitopes of Env for 8E10 and 7C4 mAb. The predicted glycosylation sites of the Env proteins are marked with bold-type letters. accession number AJ293656) after immunoprecipitation of intact virions by these anti-Env mAb. Fig. 6 shows that the 8E10 mAb precipitated intact virions at a similar level as in the polyclonal antibody raised with Env 332-615 . In contrast, mAb 7C4 as well as an unrelated mAb specific to EBV LMP1 could not pull down PERV particles. These results clearly demonstrated that 8E10, but not 7C4 mAb, exerted neutralization activity through direct binding to the Env protein on the virions.
Sequence analysis of the variable regions of the mAb
The coding regions of the V L and V H domain of the 7C4 and 8E10 mAb were obtained individually by PCR amplification using the cDNA prepared from the corresponding hybridomas. The nucleotide sequence of the amplified DNA fragments was determined and the predicted amino acid sequences were aligned using IMGT/V-QUEST (http://imgt.cines.fr:8104/ textes/vquest). Our results showed that the V L and V H of 8E10 mAb contained 108 and 117 amino acid residues, respectively. Similarly, 115 and 120 amino acid residues were determined respectively for the two mAb 7C4 variable regions. The V L gene of 8E10 was found a member of the κV3 family, while 7C4 belongs to the κV1 family. A similar analysis showed that the V H gene of 8E10 belonged to the H5 family whereas that of 7C4 was most related to H1. The sequences of these V L and V H genes have been deposited in the GenBank under the accession number AAZ91686 and AAZ91687 (for 8E10 V L and V H ) and AAZ91688 and AAZ91689 (for 7C4 V L and V H ), respectively.
Discussion
Until now the precise mechanism concerning PERV Env protein processing has not been defined clearly. Nevertheless, because of the similarity in gene organization and sequence between PERV and other C type retroviruses, it is conceivable that their Env protein maturation process is also similar. The cleavage site in Friend's MuLV, separating gp70 and p15E, is within the basic amino acid sequence Arg/Lys-X-Lys-Arg at amino acid position 480 (Akiyoshi et al., 1998; Le Tissier et al., 1997), corresponding to amino acid 434/435 in Env protein of type A PERV (Fig. 4) . As the epitope for 8E10 mAb is mapped to amino acids 427-434, and the mAb is capable of binding directly to PERV, it is concluded that the C-terminal region of gp70 is exposed on the PERV surface and is immunogenic. It has been documented that the major receptor-binding site of the related MuLV is located in the N-terminal half of gp70 (Fass et al., 1997; Kobe et al., 1999; Lavillette and Kabat, 2004) . Therefore 8E10 mAb binding to its epitope will most likely provide steric hindrance to interfere with intramolecular interaction between the C-terminal region and the receptorbinding site, an event required for subsequent membrane fusion events (Burkhart et al., 2003) . A recent report consistent with findings of this study also shows that PERV-C infectivity and host range is modulated by C-terminal region residues of its envelope gp70 protein (Gemeniano et al., 2006) . This work demonstrates that the epitope for the 7C4 mAb was mapped to a region extended out from the membranespanning domain of the p15E component of PERV Env protein.
The epitope primarily displays a coil conformation, preceded by a long α-helix. The p15E protein of retroviruses forms a dimeric structure with gp70, responsible for direct binding to the host cell receptor. Interaction between gp70 and receptor molecule on the target cell surface could trigger dimeric structure conformational change and expose the p15E, which in turn activates fusion between cellular and viral membranes (Burkhart et al., 2003; Maerz et al., 2000; Wallin et al., 2004) . Thus, the mechanism of 7C4 mAb-mediated neutralization is more likely due to blockage of p15E fusogenic activity after the virus binds to the host cell receptor. The inability of the 7C4 mAb to pull down the viral particle and a relatively high IC50 of the mAb in the neutralization assay supports this notion.
Identifying PERV-neutralizing activity in 7C4 mAb is consistent with a previous report in which goat antiserum raised with recombinant p15E protein was capable of neutralizing PERV infectivity (Fiebig et al., 2003) . Mapping the goat antibody epitopic site on p15E with overlapping peptides revealed two major antigenic sites located distinctly from the epitope of 7C4 mAb. The discrepancy may be in part due to the use of different animals in antibody production. A similar study identifying antigenic determinant on p15E component of FeLV, a close relative of PERV, demonstrated that antibody generated from different animals displayed a somewhat different antigen recognition pattern (Langhammer et al., 2005) . Both rat and goat antibodies in the FeLV study detected the two epitopes also found in their PERV study (Fiebig et al., 2003) . On the other hand, one neutralizing epitope detected only by the goat antibody, but not the rat antibody, is located in a region overlapped with the epitope identified with the 7C4 mAb. These results strongly suggest that the Env protein region from amino acid position 513 to 557, as detected by 7C4 mAb, is a neutralizing antigenic PERV determinant.
The FeLV p15E protein affects lymphocyte differentiation (Iwashiro et al., 2001 ) and CD4 + regulatory T cell expansion in response to viral infection that can lead to immunosuppression. A domain sequence LQNRRGLDILFLQEGGL is responsible for FeLV immunosuppression effect (Langhammer et al., 2005) . Interestingly, a highly related sequence, LQNRRGLDLLFLK-EGGL, is identified in PERV p15 that overlaps with the 7C4 mAb epitope. The two sequences are highly similar, therefore it would not be surprising to find that PERV p15E also possesses immunosuppressive activity. If this is the case, it will be very interesting to see whether 7C4 mAb possesses activity to block retrovirus-mediated immunosuppression.
Understanding how viral surface proteins interact with neutralizing antibodies as well as the host receptor is essential for vaccine and drug development to prevent viral infections. Such studies normally rely on the availability of structure information of both interacting proteins. A molecular structure of a completely elucidated retroviral Env protein has not existed to date that seriously hampers retrovirus infection mechanism analysis. Membrane protein crystallization is shown as often facilitated by forming complexes with specific antibody fragments that stabilize individual domains and interdomain interactions (Kwong et al., 1998) . Thus, 8E10 and 7C4 mAb availability may provide useful tools for crystallizing PERV gp70 and p15E and determining their structures.
Very little information concerning the PERV infection process has been available. The mAbs and the information obtained through this work could potentially contribute to PERV pathogenesis studies as well as many clinical applications. A synthetic peptide corresponding to the epitope of the 8E10 neutralizing antibodies for example, may be used to block virus binding to its receptor thus preventing viral infections. The epitope could induce neutralizing immunity, making it a good candidate for peptide vaccine development. Finally, the mAb could be humanized and engineered into intrabodies and used as a therapeutic agent, which may be particularly useful in preventing PERV infection in patients receiving xenotransplantation.
Materials and methods
Cell lines and viruses
Porcine kidney cell line, PK15 [ATCC CCL-33] and human embryonic kidney HEK293 cells [ATCC CRL-1573] were propagated in minimum essential medium (Sigma-Aldrich, St. Louis, MO) supplemented with 5% calf serum and 10% horse serum, respectively. The virus was precipitated from the growth medium of PK15 or PERV-infected HEK293 cells by centrifugation at 180,000×g for 60 min then resuspended in NTE buffer (100 mM NaCl, 10 mM Tris, 1 mM EDTA, pH 8.0, 0.5% bovine serum albumin). Xenotropic MuLV (ATCC VR-1447) was propagated on Mus dunni cells (ATCC CRL-2017) for 14 days to allow the virus to spread completely. Virus production was monitored by reverse transcriptase (RT) activity and plaque forming assay on PG4(S + L − ) cells as previously described (Rigg et al., 1996) . Approximately 1 × 10 4 pfu of the purified MuLV were tested to determine their cross reactivity with PERV Env mAb. Recombinant MuLV harboring a green fluorescence protein (GFP) reporter gene was obtained from HEK293 cells co-transfected with pLEGFP-c1 (Clontech, CA) and pCL-Ampho (Imgenex, San Diego, CA) and the tittered was determined on NIH3T3 cells.
Expression and purification of recombinant PERV Env protein
PERV gene fragments were obtained using PCR amplification with either cDNA or genomic DNA of PK15 cells as the template. The amplified fragments were cloned into either the pET30a or pET32a expression vector (Novagen, San Diego, CA) as indicated and clone correctness was verified by nucleotide sequencing. Resulting plasmids were transformed into Escherichia coli BL21(DE3) and hexahistidine-tagged protein synthesis was induced with 0.5 mM isopropyl-Dthiogalactopyranoside (IPTG). The IPTG-induced bacteria were harvested by centrifugation at 8000×g, disrupted by sonication, and the recombinant proteins were purified through metal chelating affinity chromatography (Novagen). Eluted protein purity was analyzed using sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE).
Western blotting analysis
Immunoblotting was used to characterize the mAb generated in this study in relation to epitope location on PERV recombinant proteins. Briefly, recombinant PERV proteins were resolved by SDS-PAGE and transferred onto a polyvinylidene difluoride (PVDF) membrane (Millipore, Bedford, MA). After blocking the membrane with 5% fat-free milk and incubation with the testing mAb for 1 h at room temperature, a 1:5000 dilution of either horseradish peroxidase-or alkaline phosphatase-conjugated secondary antibody (Jackson ImmunoResearch, West Grove, PA) was added and the reaction was continued for 1 h. After washing four times with PBS, the membrane was incubated with peroxidase substrate SK-4800 (Vector Laboratories, Burlingame, CA) or alkaline phosphatase substrates 5-bromo-4-chloro-3-indolyl-phosphate and nitroblue tetrazolium for color development.
ELISA and competition binding assay
The recombinant Env proteins (20 ng/50 μl/well) were immobilized overnight onto 96-well ELISA plates (Nalge Nunc International, Rochester, NY) at 4°C. The plates were then blocked using 1% BSA in PBS for 1 h and washed four times with PBS containing 0.05% Tween-20. The mAb was added into the antigen coated plates and incubated for 1 h at 37°C. The plate was washed thoroughly to remove unbound mAb and incubated with a 1:5000 dilution of peroxidaseconjugated goat anti-mouse IgG (Jackson ImmunoResearch) for 1 h. Finally, peroxidase substrate 2,2′-azino-di(3-ethylenthiozoline sulfonate) (Kirkegaard and Perry Laboratories Inc. Gaithersburg, MD) with H 2 O 2 was added to the reaction and incubated for approximately 15 min. The reaction was then terminated by adding 1% SDS and the result was measured spectrophotometrically at 405 nm. The competition ELISA was performed as described previously (Anderson, 1984) . The peptides used in the competition assay were synthesized by solid-phase method using FMOC-chemistry (GlycoNex, Taiwan).
Virus neutralization assay
An assay involving a single round of virus infection (Richman et al., 2003) was used to measure mAb neutralization activity. Briefly, PERV preparations derived from PK15 cells were incubated with a serially 2-fold diluted testing mAb for 1 h at 37°C. An irrelevant mAb and BSA were also included in the experiment as a negative control. The reaction mixture was then inoculated onto HEK293 cells (∼ 6 × 10 3 cells/ well) on a 12-well dish, incubated for 1 h and the inoculum was removed by washing the cells twice with PBS. Virus infectivity was determined 72 h post-inoculation by immunofluorescence analysis. Virus-incubated cells in the experiment were fixed with ice-cold 4% paraformaldehyde (Merck, Germany) for 30 min, blocked and washed as described above for the ELISA. The fixed cells were incubated sequentially with an appropriate dilution of the mAb A-11, which specifically recognizes PERV Gag protein (Chiang et al., 2005) , and FITC-conjugated secondary antibody. The infected cells were analyzed with either a fluorescence microscope or a flow cytometer (FACSCalibur™, Becton, Dickinson and Company, San Jose, CA). All experiments were performed in triplicate and neutralization percentage was calculated as [(N 0 − N t ) / N 0 ] × 100%, in which N 0 is the number of virus-infected cells without treatment and N t indicates the number of virus-infected cells with treatment. Neutralizing activity was reported as the mAb concentration required to confer 50% inhibition of the virus infection (IC 50 ). Neutralization activity of the mAb on GFP-carrying MuLV was determined directly using flow cytometry.
PERV immunoprecipitation assay
The PERV preparation from PK15 cells was incubated with 100 μg anti-Env mAb in a volume of 1 ml for 1 h at room temperature. Protein-A agarose beads were added to the mixture to capture the virus-mAb complex at room temperature for 1 h. After washing three times with 100 mM Tris-HCl, pH 8.0 and once with 10 mM Tris-HCl pH 8.0, the RNA contained in the immunoprecipitated complex was extracted using the TRI Reagent (Molecular Research Center Inc., Cincinnati, OH). The oligo(dT)-primed cDNA was synthesized employing the SuperScript Preamplification System (Invitrogen, Carlsbad, CA). The cDNA was used as a template in the subsequent PCR for detecting PERV presence.
Sequence determination of the variable region of the mAb
Total cellular RNA was extracted from the two mAbproducing hybridomas and used in reverse transcription (RT)-PCR to generate DNA fragments encoding antibody variable regions. The degenerated oligonucleotides for variable region PCR amplification were obtained from primer mixture of Mouse Scfv Module/Recombinant Phage Antibody Kit (Amersham-Pharmacia Biosciences, NJ). The PCR amplified DNA fragments were cloned into pGEM-T Easy vector (Promega, Madison, WI), and their nucleotide sequence determined and translated into protein sequence using the Vector NTI Suite VII for analysis (Invitrogen, Carlsbad, CA) .
